第 1 到 29 筆結果,共 29 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2016 | Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors | BIN-CHI LIAO ; CHIA-CHI LIN ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Journal of Biomedical Science | 43 | 37 | |
2 | 2015 | Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy | BIN-CHI LIAO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG | Therapeutic Advances in Medical Oncology | 16 | 16 | |
3 | 2018 | Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Opinion on Pharmacotherapy | 5 | 5 | |
4 | 2015 | Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancer | Ta-Chen Huang ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-KANG TU | Japanese Journal of Clinical Oncology | 30 | 27 | |
5 | 2019 | Should we design clinical trials differently in the era of cancer immunotherapy? | CHIA-CHI LIN | Journal of Immunotherapy and Precision Oncology | 3 | 0 | |
6 | 2011 | RET mutations and medullary thyroid cancer | CHIA-CHI LIN | Journal of the Formosan Medical Association | 2 | 0 | |
7 | 2018 | Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma | Yang P.-C.; JHE-CYUAN GUO ; MIN-SHU HSIEH ; CHIA-CHI LIN ; CHIH-HUNG HSU | Journal of Thoracic Oncology | 6 | 4 | |
8 | 2013 | Reply to S. Vale | CHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU | Journal of Clinical Oncology | 0 | 0 | |
9 | 2020 | Rational combination with an immunotherapy backbone in genitourinary cancers | JHE-CYUAN GUO ; CHIA-CHI LIN | Urological Science | 3 | 3 | |
10 | 2011 | Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC | Medema R.H.; CHIA-CHI LIN ; CHIH-HSIN YANG | Clinical Cancer Research | 60 | 58 | |
11 | 2017 | Optimal usage of radium-223 in metastatic castration-resistant prostate cancer | Cha T.-L.; Wu T.T.-L.; Vogelzang N.J.; CHAO-YUAN HUANG ; Huang S.-P.; CHIA-CHI LIN ; Ou Y.-C.; Pang S.-T.; Shen D.H.-Y.; Wu W.-J.; Chang W.Y.-H. | Journal of the Formosan Medical Association | 15 | 14 | |
12 | 2011 | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations | CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 10 | 10 | |
13 | 2017 | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | BIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Lung Cancer | 38 | 35 | |
14 | 2007 | Novel targeted therapies for advanced esophageal cancer | CHIA-CHI LIN ; Papadopoulos K.P. | Diseases of the Esophagus | 12 | 12 | |
15 | 2017 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Oncology Reports | 19 | 19 | |
16 | 2017 | New data on clinical decisions in NSCLC patients with uncommon EGFR mutations | Wu T.; Hsiue E.H.; JIH-HSIANG LEE ; Chia-Chi Lin ; CHIH-HSIN YANG | Expert Review of Respiratory Medicine | 15 | 14 | |
17 | 2009 | National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital | CHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO | Drug Information Journal | 3 | 2 | |
18 | 2022 | Immunotherapy in anaplastic thyroid cancer: Case series | SHYANG-RONG SHIH ; Chen, Kuan-Hua; Lin, Kuan-Yu; PAN-CHYR YANG ; KUEN-YUAN CHEN ; CHUN-WEI WANG ; Chun-Nan Chen ; CHIH-FENG LIN ; CHIA-CHI LIN | Journal of the Formosan Medical Association = Taiwan yi zhi | 7 | 6 | |
19 | 2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |
20 | 2013 | First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 15 | 16 | |
21 | 2009 | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer | CHIA-CHI LIN ; CHIH-HSIN YANG | Targeted Oncology | 11 | 9 | |
22 | 2021 | Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm | Chang, Ling-Kai; Chen, Kuan-Chih; MEI-FANG CHENG ; CHIA-CHI LIN ; HSIU-PO WANG ; Sung, Chia-Tung; Chen, Jou-Ho; RUOH-FANG YEN ; CHIA-LIN HSU ; SHYANG-RONG SHIH | Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society | 2 | 2 | |
23 | 2013 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | HSIANG-FONG KAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Future Oncology | 7 | 6 | |
24 | 2023 | Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer | JHE-CYUAN GUO ; Hsu, Chia-Lang; MIN-SHU HSIEH ; CHIA-CHI LIN ; TA-CHEN HUANG ; HUNG-YANG KUO ; YU-YUN SHAO ; CHIH-HUNG HSU | Thoracic cancer | 0 | 0 | |
25 | 2022 | Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies | Shimizu, Toshio; Kuboki, Yasutoshi; CHIA-CHI LIN ; Yonemori, Kan; Yanai, Tomoko; Faller, Douglas V; Dobler, Lwona; Gupta, Neeraj; Sedarati, Farhad; Kim, Kyu-Pyo | Targeted oncology | 0 | 0 | |
26 | 2016 | Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer | Chen, Kai-Lung; CHIA-CHI LIN ; YUNG-TSU CHO ; Yang, Che-Wen; YI-SHUAN SHEEN ; Tsai, Hsiao-En; CHIA-YU CHU | JAMA Dermatology | 29 | 20 | |
27 | 2019 | Challenges of the phase I drug development in non-small cell lung cancer | CHIA-CHI LIN | Chinese Clinical Oncology | 7 | 8 | |
28 | 2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 33 | 30 | |
29 | 2022 | Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors | Wu, Tsung-Che; CHIA-CHI LIN | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2 |